Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

By B. Gage, Yan Yan, P. Milligan, A. Waterman, R. Culverhouse, M. Rich, M. Radford. American Heart Journal, 2006

1,072 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report (2012, background): “Following age and prior bleeding, the most prevalent bleeding risk factors included in the scores are anemia,(69,99-102) renal disease,(69,98,99,101) hypertension(69,102) or uncontrolled systolic BP,(98) concomitant antiplatelets,(98,101,102) and alcohol excess,(98,99,102) and prior stroke(98,99) or”
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “Compared with low-risk patients, moderate-risk patients are assumed to have a twofold risk and high-risk patients are assumed to have an eightfold risk of major bleeding.(79,185,187,189,195,196,198,204) We estimate that anticoagulation is associated with a 2.”
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, methodology): “51,52 With release of initial results from the SHARP (Study of Heart and Renal Protection) trial, statins may now be the best-studied medical therapy in the context of advanced CKD.”